Vol. 5 No. 2 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Tabassum , et al - 2026

Microbial Interactions Within Human Microbiomes and Their Influence on Immunity, Metabolism, and Health

Dr. Tahira Tabassum

Associate Professor, Chairperson/HOD, Department of Pathology, Sargodha Medical College, Sargodha, Pakistan

Shaista Gul

Ibadat International University, Islamabad, Pakistan

Syeda Aneela Azad

Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University, Islamabad, Pakistan

Ghulam Abbas Baki

Department of Eastern Medicine, University of Poonch Rawalakot, Azad Jammu and Kashmir, Pakistan

Dr. Sadia Zia

Principal Lecturer, Department of Biotechnology, University of Central Punjab, Lahore, Pakistan

Tahani R. K. Bsharat

Faculty of Graduate Studies, An-Najah National University, Nablus, Palestine

Ebrahim Alinia-Ahandani

Food and Drug Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran

Momina Iftikhar

Faculty of Eastern Medicine, Government College University Faisalabad Pakistan

Naveed Ayyaz

DVM Faculty of Veterinary and Animal Sciences, University of Poonch, Rawalakot, Azad Jammu and Kashmir, Pakistan

Akif Saeed

CH Director, Medical Services and Research, Hope Family Clinic & Rehab, Faisalabad, Pakistan

Maryam khalid*

Department of Parasitology, University of Veterinary and Animal Sciences Lahore (UVAS), Pakistan

Corresponding Author Email: maryammano450@gmail.com

Vol. 4 No. 3 (2025)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Author Details

Keywords: Human microbiome, gut microbiota, immunity, metabolism, dysbiosis, personalized medicine, probiotics.

Received on 05 May 2026
Accepted on 19 May 2026
Published on 21 May 2026

Corresponding E-mails & Authors*:
Maryam khalid*
maryammano450@gmail.com

Abstract

The microbiome of humans is made up of many kinds of microorganisms (bacteria, viruses, fungi, and archaea) found in different places within us. These communities help sustain our healthy physiological state and are involved in immune system regulation, metabolic activities, and all aspects of health. Developments in understanding how the microbes interact and how microorganisms interact with their human hosts include metagenomics, next-generation sequencing, and systems biology. Gut bacteria, in particular, help with producing nutrients, synthesizing vitamins, creating short-chain fatty acids, maintaining the intestinal barrier, and helping to regulate immune function. Changes in the balance of chemicals within gut bacteria, referred to as dysbiosis, have been linked to many diseases, including obesity, diabetes, inflammatory bowel disease, allergic reactions, rheumatoid arthritis, and neurological disorders. New research shows that the interactions among microbes are able to influence signalling pathways, inflammation, and metabolic control through a variety of molecular mechanisms. Furthermore, microbiota-based therapies such as probiotics, prebiotics, synbiotics, dietary changes, and faecal microbiota transplantation are increasingly seen as effective methods for both prevention and treatment of disease. Personalized medicine approaches that involve profiling the microbiome may allow individualised treatments and better outcomes in patients.

INTRODUCTION

Human microbiomes consist of billions of different kinds of microorganisms that live on or in virtually every area of the human body. Most of these microorganisms are located within the gastrointestinal (GI) tract, but they can also be found on the skin, in the mouth, in the respiratory tract, and in the

urogenital tract. Microbial populations contain many different types of microorganisms (e.g., bacteria, viruses, fungi and archaea) that exist with the host (the human being) in a variety of dynamic ecological relationships (Turnbaugh et al., 2007). New advancements made in the field of molecular biology through high-throughput sequencing technology have completely changed our understanding of microbial communities and their role in maintaining human health.

A significant microbial ecosystem is found in the gastrointestinal tract. The microbes amount to numbers that are equal to human cells, making them key to many bodily functions (Sender et al 2016). Microbes in the gut aid in digestion, vitamin synthesis, metabolizing energy, absorbing nutrients from the diet and help to mature parts of the immune system (Flint et al 2012). Many of the microorganisms in the gut also help support the host's health.

The diversity of microorganisms is one of the most important factors that influence the stability and functionality of microbiomes. A healthy microbiome consists of a variety of species that interact with one another, both in a collaborative fashion as well as in a competitive manner. The interactions between microbes contribute to the prevention of the establishment of pathogenic organisms, maintaining the integrity of epithelial barriers, and regulation of immune homeostasis (Belkaid & Hand, 2014). Changes in the microbial community structure can disrupt these functions and lead to increased susceptibility to disease. The human immune system and the microbiome have a constant bidirectional communication. Microbial products/metabolites and components of the microbial cells affect the development and functionality of the immune system, while immune responses alter the diversity and composition of the microbiome (Honda & Littman, 2016). Commensal microorganisms aid in the generation of regulatory T-cells, promote tolerance to innocuous antigens, and provide a means to suppress excessive inflammatory responses. These interactions are essential to maintaining the immune system's ability to regulate itself and to protect the host against infectious agents.

The metabolism of microbes affects much of the physiology of their hosts. The fermentation of dietary fibers by bacteria in the gut produces short-chain fatty acids such as acetate, propionate and butyrate; these metabolites affect energy homeostasis, regulate glucose metabolism, lipogenesis and inflammatory pathways (Koh et al., 2016). Additionally, the microbial metabolites also interact with the endocrine and nervous systems; therefore, microbiome has been shown to exert a powerful effect on many biological functions of its host. It has been demonstrated that the perturbation of microbial communities, which is generally referred to as dysbiosis, is

associated with numerous chronic diseases. Chronic diseases that have been associated with changes in the composition of microbial communities are: obesity, type 2 diabetes, inflammatory bowel disease (IBD), colorectal cancer, allergies & asthma, and autoimmune diseases (Lynch & Pedersen, 2016). In addition, studies conducted recently have shown that there are important relationships between gut microbiota and several neurological conditions through the microbiota-gut-brain axis (Cryan et al., 2019).

Research into microbial diversity and function has sped up greatly due to international initiatives such as the Human Microbiome Project. It has been well established through these projects that the composition of the microbiome of individuals is very different from one another but does share similar functional characteristics among those who are healthy (Human Microbiome Project Consortium, 2012). The information gained through the Human Microbiome Project has been instrumental in developing therapies targeting the microbiome. The goal of personalized medicine is to develop medical interventions based on each patient's individual biological characteristics. Adding microbiome data into personalized medicine could allow for the ability to better predict, prevent, and treat diseases in the future. In addition, microbiome profiling gives researchers a new way to discover potential biomarkers for diseases and develop targeted strategies for nutrition and medicine tailored to an individual's needs (Gilbert et al., 2018). This paper reviews the composition of the human microbiome, interactions amongst microorganisms, the mechanisms by which the microbiome influences metabolic function and immunity, associations of disease, and the use of the microbiome in developing new therapies. Understanding these complex relationships will be important for the future of microbiome-based interventions and health outcomes.

Materials and Methods

A comprehensive literature search was performed in the scientific database (PubMed, Scopus, Web of Science and Google Scholar) using the keywords "gut microbiota," “human microbiome,” “immune system,” “metabolism,” “dysbiosis,” and “personalized medicine.” Studies published between 2000 and 2025 and written in English were searched for. Original research articles, systematic reviews, meta-analyses, and landmark microbiome studies were included in this review. Information was extracted, synthesized, and organized thematically with regard to microbiome composition, microbial interactions, immune regulation, metabolic processes/function, disease associations, and therapeutic uses of the microbiome.

Table 1. Major Human Microbiota and Their Health Functions

Microbial Group	Primary Location	Major Functions	Health Significance	Reference
Bacteroides spp.	Colon	Carbohydrate metabolism, SCFA production	Energy homeostasis and gut health	Bäckhed et al., 2005
Firmicutes	Intestine	Fiber fermentation, butyrate production	Immune regulation and metabolism	Flint et al., 2012
Lactobacillus spp.	Gut, vagina	Lactic acid production	Pathogen inhibition	Kho & Lal, 2018
Bifidobacterium spp.	Colon	Oligosaccharide fermentation	Infant health and immunity	Arrieta et al., 2014
Akkermansia muciniphila	Mucosal layer	Mucin degradation	Metabolic regulation	Fan & Pedersen, 2021
Faecalibacterium prausnitzii	Colon	Butyrate production	Anti-inflammatory effects	Koh et al., 2016
Oral Streptococci	Oral cavity	Biofilm formation	Oral ecosystem stability	Gilbert et al., 2018
Skin Staphylococci	Skin	Barrier protection	Prevention of pathogen colonization	Belkaid & Hand, 2014
Methanogenic Archaea	Intestine	Methane production	Digestive ecosystem balance	Jandhyala et al., 2015
Commensal Fungi	Gut and skin	Immune modulation	Maintenance of microbial diversity	Honda & Littman, 2016

Human Microbiome: Composition and Diversity

Many different kinds of organisms (a.k.a. microbes) live in many places on your body; for instance, microbes are abundant in the gastrointestinal tract, the oral cavity, the skin, the respiratory tract, and the genitourinary system (the parts of the body concerned with reproductive and urinary functions). Bacteria, fungi, viruses, archaea, and protozoa comprise the human microbiome and collectively provide benefits to your body's systems and your overall health. Among these habitats, the gastrointestinal tract has the highest concentration of microbes. The trillions of microbes in the gastrointestinal tract are involved in several biological processes (Cho & Blaser, 2012). A healthy microbiome is characterized by abundance (the total number of microorganisms) and diversity (the variety of different organisms), which reflect both the abundance and variety of microorganisms. A diverse

microbiome will provide stability and resiliency in the face of environmental changes associated with infections, dietary changes, and antibiotic exposure (Ley et al., 2006). Conversely, lower microbial diversity is associated with numerous diseases, for example, obesity, inflammatory bowel disease, and metabolic syndrome.

The majority of the gut microbiome is made up of a type of bacteria called phylum, which includes Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia. Of these five major types, Firmicutes and Bacteroidetes are the most abundant types of bacteria in the gut and are also responsible for carrying out many of the important functions of the gut microbiome, such as fermentation of carbohydrates and production of short-chain fatty acids (Bäckhed et al., 2004). Several members of Actinobacteria, specifically Bifidobacterium species, play an important role in the development of the immune system and digestion of complex carbohydrates. The colonization of the gut by these microorganisms begins at birth and continues for the rest of life. There are several factors that can affect how the microbiome develops during life, including how the baby is delivered, whether breastmilk is provided, what foods are consumed, contact with the outside world, use of antibiotics, and the genetic makeup of the host (Arrieta et al., 2014). Babies that are delivered vaginally are typically colonized with microorganisms that are similar to those found in their mother's vagina (i.e., maternal vaginal microbiota), however, babies that are delivered by c-section often have delayed colonization of beneficial types of bacteria. The composition of human milk oligosaccharides in breastmilk can also help promote the growth of Bifidobacterium species during this infant period.

Another highly diverse ecosystem is the oral microbiome. More than 700 species of microorganisms reside in the mouth, contributing to the prevention of disease and promotion of oral health. Comensal organisms form biofilms, inhibit pathogenic organisms, and help to maintain the ecological balance. When these communities are disrupted (i.e., dysbiosis), they may contribute to dental disease, periodontal disease, and/or systemic inflammation (Gilbert et al., 2018). The skin microbiome differs based on location (anatomical), moisture content and temperature, and the activity of sebaceous glands. In general, the most common genera include Staphylococcus, Corynebacterium, and Cutibacterium. These organisms serve to prevent pathogen colonization, and they influence the immune system through their interactions with skin immune cells (Belkaid & Hand, 2014). Metagenomic sequencing has revolutionized our ability to study microbiomes, allowing us to fully characterize microbial communities without the need for culture-based techniques. High-throughput sequencing technologies enable us to identify microbial species and their genes, and some genomic sequences allow us to better understand how microorganisms function and interact with their hosts (Human Microbiome Project Consortium, 2012).

While there is much discrepancy in terms of the composition of microorganisms between individuals, microbial populations are functionally redundant across their respective ecosystems. That is, many different species of microorganisms and taxonomic groups provide the same or similar metabolic functions, which means that physiological systems of life can continue to function as needed despite variability in taxonomic makes up. Functional redundancy plays an important role in contributing to both ecological and host health/viability. The human microbiome is representative of a complex, ever-changing ecological system with a significant effect on numerous physiological functioning. Therefore, understanding the diversity and composition of the human microbiome is essential to understanding how a person becomes healthy or unhealthy, and will help develop specific microbiome-based therapeutic approaches to health care..

Microbial Interactions Within the Microbiome

The microorganisms that perform specific roles in microbial communities form a large number of intricate networks of interactions with one another as well as between each organism of the community and the host. Some examples of the types of interaction that occur between organisms are mutualism, commensalism, competition, predation, and cooperation. All of these interactions can be defined by ecological relationships that provide the ability of a specific microbial community to establish their structure, maintain their stability, and function (Sommer & Bäckhed, 2013). Mutualistic interactions occur when both microorganisms and their hosts benefit from their relationship. For example, when gut bacteria get nutrients and a suitable environment from the host, gut bacteria provide assistance to the host in digestion, synthesize vitamins, and regulate the host's immune response. These types of mutualism are fundamental components of host-microbe symbiosis and help to maintain physiological homeostasis (Bäckhed et al., 2005). Competition between the microorganisms in a given microbial community is a significant ecological mechanism. Commensal bacteria compete with pathogenic bacteria for nutrients, attachment sites, and environmental resources. This mechanism of resistance to colonization by pathogenic bacteria prevents excessive growth of these pathogenic organisms and plays an important role in protecting a host against infectious disease (Round & Mazmanian, 2009). In addition to competing for nutrients and resources, beneficial microorganisms may produce antimicrobial compounds to eliminate pathogen competitors from a given niche (such as bacteriocins).

Inter-relationships between microorganisms of different species through mutual support are common in the microbial community that exists in the digestive tract. Microorganisms produce products as a result of their metabolic activity, some of which can be used as a "food source" for another organism. For example, some microorganisms produce an end product of fermentation (short-chain fatty acids) after fermenting dietary fibre (Koh et al., 2016) Thus, cooperative interactions contribute to enhanced metabolic efficiency and to increased functional capability of a microbial ecosystem. Another important mechanism of communication between microorganisms is quorum sensing. Microorganisms produce chemical signalling molecules (for example, homoserine lactones) that allow them to communicate with other microorganisms in the same area and/or to communicate when their population density has reached a certain level. Through quorum sensing, microorganisms regulate a variety of activities, including biofilm formation, production of virulence factors, use of nutrients, and the organization of their communities (Jandhyala et al., 2015). Microbial biofilms (highly organized communities of microorganisms surrounded by an extracellular matrix) can protect against environmental factors, as well as assist other microorganisms in metabolic cooperation. Microbial biofilms contribute to the ecological stability of an environment and increase resistance to microbial pathogens through their development in the gastrointestinal tract and oral cavity.

Microbial interactions, a consequence of the bacteriophages' ability to infect bacterium, also affect the community of microorganisms that inhabit any given environment (Gilbert et al. 2018). The bacteriophages have an important role in regulating the diversity of bacteria through the regulation of the population of bacteria and transfer of genes between them. The regulation of bacterial populations by bacteriophages contributes to the overall balance of ecosystems as well as having the potential to affect the host's health. In addition to the bacteriophages, there are several factors that affect the relationships between microorganisms, including host factors. Through the immune system, the host can selectively enhance the growth of beneficial microorganisms while simultaneously inhibiting the growth of microorganisms that may cause harm (Honda and Littman 2016). Various host factors, such as antimicrobial peptides and secretions of mucus, promote and diminish the growth of various species of microorganisms. Moreover, dietary consumption is one of the strongest environmental factors affecting microorganism relationships. The consumption of various dietary fibers will enhance the growth of beneficial, fermenting microorganisms, whereas high-fat and low-fiber diets tend to promote the growth of microorganisms associated with inflammation or metabolic dysfunction. Long-term dietary patterns have an impact on the diversity of microorganisms and their functional characteristics (Fan and Pedersen 2021). There is emerging evidence to suggest that the interactions amongst microorganisms can occur not only within the gastrointestinal tract, but also at different parts of the body, through the use of various systemic signaling mechanisms. These signals will ultimately influence the response of the immune system to injury and inflammation, the regulation of the endocrine system and communicate with the nervous system ways in which the host and the microbiome can interact (Cryan et al. 2019). Lastly, the interactions of microorganisms will determine the functional capabilities of microbiomes and will influence the physiological effects of the host. Understanding the interconnections between these communities of microorganisms is critical for developing new treatment approaches and for exploring ways to enhance the treatment of chronic diseases and other disabilities.

Influence on Immune System Development and Function

A healthy immune system and microbiome work hand-in-hand. In fact, many microbes our bodies are exposed to at a young age allows us to develop a healthy immune system. In the absence of a colonized microbiota, there is overwhelming evidence from germ-free animal studies that the immune system will not develop, and therefore it is clear that the maternal/microbiota relationship is critical for the education of the immune system (Belkaid & Hand, 2014). The intestinal microbiome is important for the formation of lymphoid tissues associated with the gut, which represent a significant portion of mucosal immunity. The antigens produced by these bacteria drive the development and maturation of both the

innate and adaptive immune response through the stimulation of immune cells and their differentiation. Through these processes, the immune system is able to develop competent responses while simultaneously maintaining the necessary tolerogenic responses to healthy microorganisms (Honda & Littman, 2016). Commensal species of bacteria can also modulate the activity of regulatory T-cells, which prevent overzealous immune responses and the development of autoimmune disease. The phylogenetic group of bacteria that are particularly influential on the developed population of regulatory T-cells, and therefore, influence production of anti-inflammatory cytokines. This process has been shown to promote immune tolerance and tissue homeostasis (Round & Mazmanian, 2009).

Also a function of various microbial metabolites (for example: short-chain fatty acids) on immune function is regulation. While butyrate promotes the differentiation of regulatory T-cells and improves the integrity of the intestinal barrier (and subsequently reduces inflammatory responses) (Koh et al., 2016), short-chain fatty acids, such as acetate, propionate, and butyrate, also possess anti-inflammatory qualities via modulation of several key immunological signaling pathways and gene expressions. The intestinal epithelial barrier plays an essential role in providing the primary interface between the host tissues and the colonizing microbial community. The beneficial microorganisms that comprise the colonizing microbiota (the gut microbiome) enhance the function of the intestinal epithelial barrier by stimulating mucus production, the expression of proteins associated with tight junction formation, and the epithelial mechanisms of repair. The loss of barrier integrity results in the translocation of microbial-associated products and the development of a chronic inflammatory response (Lynch & Pedersen, 2016). Microbial ecology provides a protective mechanism against infection by pathogenic microorganisms through colonization resistance. Competitive advantage (competition for nutrients and ecological niches) is utilized by the colonizing microbiota to prevent pathogen establishment and outgrowth. Commensal (i.e., non-pathogenic) bacteria also promote the production of antimicrobial peptides and immunoglobulin A, which serve as mucosal defenses (Honda & Littman, 2016).

Research has shown that problems with the normal composition of microbes in the gut can lead to allergies and autoimmune diseases. For instance, there is evidence that children with asthma, eczema, or gastrointestinal diseases have lower levels of good bacteria in their intestines than children without these conditions. We believe this suggests that disturbance of the intestinal microbes could affect the normal function of the immune system, resulting in excessive inflammation and eventually causing the immune system to produce too many immune cells or antibodies that react against normal body's own tissues (Arrieta and colleagues, 2014). The bacteria that live in our intestines also produce metabolites (small molecules) that enter circulation and affect the immune system located in other areas of the body, including the lungs, liver, and central nervous system. As a result, it appears that the intestinal bacteria will play an important role in regulating and maintaining the function of the immune system. Therefore, maintaining healthy, diverse populations of intestinal bacteria is an essential part of maintaining balance within the body, as well as for avoiding diseases that are caused by imbalances among the parts of the immune system itself.

Microbiome and Metabolic Regulation

One of the most significant influences on host metabolism is the gut microbiota because it has many different types of metabolic capabilities and a close functional relationship with the gastrointestinal tract. The overall microbial genome includes millions of genes that code for enzymes that cannot be found in the human genome. Therefore, the gut microbiota permits digestion of dietary components that humans are unable to digest by converting dietary components into short-chain fatty acids (SCFAs) through the fermentation of complex carbohydrates and fibre; these fatty acids include acetate, propionate and butyrate. Humans are unable to digest numerous types of plant polysaccharides due to the lack of enzymes for their degradation; therefore, gut bacteria are accountable for breaking down these plant polysaccharides into SCFAs. SCFAs are a source of energy for colon cells, affect the inflammatory response, and have an effect on the host's overall metabolic rate. Butyrate is the primary source of energy for intestinal epithelial cells and plays a key role in maintaining intestinal permeability. Propionate contributes to gluconeogenesis in the liver and acetate enters peripheral tissues for lipid production and energy metabolism. Collectively, SCFAs serving as key regulators of host physiology help to maintain host metabolic balance.

Gut flora (the bacteria that live in your intestines) modifies how much energy we absorb from food. By working together, different types of bacteria can help extract calories from the food you eat, which can lead to an increase in body fat and obesity. A study done by Bäckhed et al., found that germ-free mice (Mice without gut Flora) have significantly less body fat than do conventionally raised mice, indicating that gut Flora plays a role in regulating energy (calories). Bacteria are also involved with the conversion of primary bile acids into secondary bile acids. This conversion produces what are known as secondary bile acids. Both primary and secondary bile acids act as signaling molecules that regulate glucose metabolism, lipid absorption, and energy expenditure via the activation of the nuclear receptor or G protein-coupled receptor (Fan & Pedersen, 2021). Disruption of bacteria's ability to convert bile acids into secondary bile acids has been linked to being obese, having diabetes, or having liver

diseases. Bacteria are also important for our body because they manufacture vitamins. Many types of bacteria produce vitamins, specifically vitamin K, biotin, folate, riboflavin, and vitamin B12. These vitamins are needed for multiple physiological activities, such as assisting in blood clotting, assisting our nervous systems, and aiding cells in carrying out metabolic processes (Jandhyala et al, 2015).

The interaction between gut microbes and the host endocrine system also has an impact on overall metabolism. Gut bacteria produce hormones like GLP-1, Peptide YY, and ghrelin that affect appetite regulation, satiety, insulin release, and energy balance (Fan & Pedersen, 2021). These studies are evidence that the microbiome is an endocrine organ providing communication with tissues located further away. There are also numerous emerging studies indicating that metabolites produced by gut bacteria can affect mitochondrial function, oxidative stress, and cellular energy production. By modulating metabolic pathways at the cellular level, the microbiome plays a significant role in maintaining physiological homeostasis and the prevention of metabolic disease. As such, the gut microbiome functions as one of the major regulators of metabolic health. If the composition of the microbiome is disrupted, it can lead to the development of obesity, insulin resistance, diabetes, or heart disease. This highlights the importance of maintaining the balance of the microbiome by active dietary or pharmacologic interventions.

Microbiome Dysbiosis and Human Diseases

Dysbiosis is defined as an imbalance in microbial diversity, microbial composition, or microbial function, resulting in disrupted host-microbe homeostasis and causing disease. Antibiotic use, diet changes, infections, environmental toxins, chronic stress, and aging can all change the composition of the microbes living in and on us and lead to dysbiosis (Cho & Blaser, 2012). One of the conditions that has been studied the most in relation to dysbiosis is obesity and metabolic syndrome. The gut microbiotas of persons with obesity typically have altered microbial diversity with changes in the relative abundance of Firmicutes and Bacteroidetes. Changes in the gut microbiota may allow for greater energy extraction from food leading to an increase in fat accumulation (Bäckhed et al., 2004). Dysbiosis has also been associated with type 2 diabetes, where patients with type 2 diabetes frequently have reduced numbers of beneficial bacteria, such as butyrate producers, and increased levels of pro-inflammatory microbes. These changes ultimately lead to insulin resistance, chronic inflammation, and glucose metabolism dysregulation (Fan & Pedersen, 2021). Crohn's disease and ulcerative colitis (inflammatory bowel disease) also have been found to be associated with dysbiosis, as there is generally less microbial diversity and decreased levels of the anti-inflammatory Faecalibacterium prausnitzii, with these alterations contributing to mucosal inflammation and intestinal barrier dysfunction (Lynch & Pedersen, 2016).

The microbiome is thought to be involved in allergic conditions such as asthma, eczema and food allergies. The theory behind the Hygiene Hypothesis suggests that a lack of exposure to microbes during early childhood may lead to insufficient immune development and increase the risk of developing these types of allergic conditions (Arrieta et al., 2014). Rheumatoid arthritis, multiple sclerosis and Type 1 diabetes are also believed to be associated with disrupted or altered microbial communities in the body. The process of dysbiosis is believed to create conditions in the body that allow for autoimmune response through immunological cross-reactivity, epithelial barrier breakdown (ie leaky gut), and abnormal activation of the immune pathway (Honda and Littman, 2016). Research shows that the stomach and brain communicate with each other through the gut-brain axis, and that any changes in the microbial composition in the gastrointestinal tract may also result in the development of anxiety and depression. Autism, Parkinson's or Alzheimer's have also been linked to alternations in GI microbial composition. Microbial products created during digestion as well as immune mediators and neural pathways all work together to help facilitate these communicative processes between the gut and the brain (Cryan et al., 2019). Cancer has also been found to be associated to microbial dysbiosis. There are many ways that microorganisms promote the development of cancer; by producing genotoxic compounds, by inducing local or systemic inflammation over an extended period of time and/or by modifying the body's immunological response to a specific stimulus.

Therapeutic Applications and Personalized Medicine

The recent increase in interest in understanding the relationship between the microbiome and health has led to the exploration of potential ways to use the microbiome to improve health via new therapeutic interventions; i.e., to restore the natural balance of microbes in the body, enhance the positive functions of the microbes, and/or reduce the likelihood of diseases occurring due to imbalances in that ecosystem (e.g., dysbiosis). Probiotics are one of the major forms of treatment targeting the microbiome; they are living microorganisms that, when given in sufficient numbers, can provide health benefits. Lactobacillus, Bifidobacterium and other species of bacteria often referred to collectively as "probiotics" provide beneficial health effects by improving the integrity of the intestinal barrier, modulating the immune response to invading organisms, and inhibiting the growth and action of harmful, disease-causing bacteria (Kho & Lal, 2018). Prebiotics are non-digestible substances that stimulate the growth of beneficial microbes by providing them with food; common examples include inulin, fructo-oligosaccharides, and galacto-oligosaccharides. As prebiotics promote the growth of beneficial microorganisms, they positively impact metabolic and immune health (Flint et al., 2012). Synbiotics are a combination of probiotics and prebiotics that produce additive or synergistic effects. Based on the results of clinical trials, synbiotics may promote the optimal functioning of the gastrointestinal system by reducing inflammation and increasing microbial diversity.

The potential benefits of fecal microbiota transplantation (FMT) are a good example of a new and potentially effective treatment. FMT is the transfer of stool from a healthy person into a person who has lost the normal balance of different types of bacteria in the gut; this person is referred to as having "dysbiosis." The use of FMT has already shown great potential for treating recurrent Clostridioides (Clostridium) difficile (C. diff) infections, and currently an investigation is underway to study its effectiveness in treating inflammatory bowel disease (IBD), metabolic diseases and neurological diseases (Lynch & Pedersen, 2016). Diet is another powerful method for changing the composition of a person's gut microbiome. When one eats large amounts of dietary fibre, fruits, vegetables, and fermented foods, the diversity of the gut microbiome is increased, and beneficial metabolites are created; however, eating large amounts of processed food and saturated fats can also lead to dysbiosis and increased inflammation in the gut (Fan & Pedersen, 2021). Advances in the scientific fields of metagenomics, metabolomics, and artificial intelligence have made the development of microbiome-based personalized medicine possible. The unique microbiome of an individual can provide insight into the risk of developing certain diseases, the person's response to specific medications, and the person's nutritional needs. Personalized treatment based on an individual's microbiome may help to increase the effectiveness of treatment and decrease the likelihood of harmful side effects (Gilbert et al., 2018). Some of the future directions of microbiome therapy may include the use of engineered probiotics, supplementation with microbial metabolites, bacteriophage therapy, and precisely modulating an individual's microbiome. The potential impact of these new therapies may change the manner in which we will and treat diseases.

Future Perspectives

Research on the microbiome is progressing rapidly, opening up many new opportunities to further understand human health and illness (particularly how the microbiome contributes to these factors). New technologies related to sequencing, computational biology (especially those associated with understanding how systems medicine works), and systems biology will lead to new ways to better understand the environment in which microbes exist, and how they interact with their hosts; i.e., humans. Future studies should focus on establishing causal links between microbiota changes and disease outcomes. There have been many theory-based associations identified between changes in the microbiota and different diseases; however, there is still not a complete mechanistic understanding of how or why the microbiome contributes to many different medical conditions. Therefore, longitudinal studies and controlled experiments will be necessary to test the efficacy of many microbiome-based treatment strategies / interventions. When combined with other omics technologies (such as genomics, proteomics, metabolomics, etc.) and clinical information, microbiome data may enable the creation of integrated frameworks for delivering precision medical care. This will likely allow for earlier diagnosis of diseases, more individualized forms of treatment, and improved health outcomes for patients receiving care. Artificial intelligence and machine learning will likely be essential for analyzing and interpreting complex microbiome datasets. These technologies will help to establish thresholds / criteria for predicting microbial signatures and developing personalized treatment paradigms. Continued research in the area of microbial metabolites, bacteriophages, and the signaling pathways involved in the microbiome will help to uncover new therapeutic target opportunities. Furthermore, developing regulatory structures and standardized methodologies for evaluating and studying the microbiome are crucial for successful clinical application and wider adoption of microbiome-based treatment approaches.

Limitations

Microbiome research kind of hits a few limitations, like people vary a lot, there are methodological differences, some odd sampling biases, and then there's the bigger issue—proving cause and effect in a clean way. A pretty decent number of studies end up being more observational than anything else, so it's hard to claim anything that's truly solid about how the microbial side is actually involved in disease. More longitudinal work plus mechanistic investigations are still needed, to validate what's been observed, and to make the outcomes more clinically usable in real practice.

Recommendations

Future research should put more emphasis on standardized methods for microbiome analysis , so the findings are a lot easier to compare across different studies. We likely need longitudinal work too , meaning repeated observations over time , to sort out whether microbial shifts are really causing disease rather than just showing up alongside it . Also, clinical trials that test probiotics , prebiotics, synbiotics , and even microbiome targeted therapies should be scaled up. It seems pretty promising that bringing microbiome profiling into personalized medicine could help with better prevention strategies and more tailored care , because you can match the approach to the individual. On top of that , public health programs that encourage sensible diet habits and responsible antibiotic use might help keep the beneficial microbial communities stable , and in the end , lower overall disease risk .

Conclusion

The human microbiome is kinda like this tangled, constantly evolving ecosystem , and it really matters a lot for immunity, metabolism, and general wellbeing too. How these microbes communicate, and how they end up forming these uneasy alliances, can nudge bodily routines through different routes , for instance , by grabbing hold of nutrients, tweaking immune signaling , and even making space for this intercellular give and take type of thing. With newer sequencing tools, researchers have been able to look more closely into host–microbe relationships , and it seems like microbial diversity is sort of a key ingredient for staying steady, or homeostasis, as they call it. But once that balance gets shoved off course, dysbiosis tends to show up again and again across a bunch of conditions. Metabolic trouble, inflammatory states, autoimmune disorders, neurological complications , and yes, cancer too. Newer strategies, like probiotics, prebiotics, fecal microbiota transplantation, and other more customized microbiome interventions, are starting to look like real chances for preventing disease, or helping existing therapies work more smoothly. If the research keeps moving forward , blending microbiology with immunology, metabolomics, and precision medicine in the same breath, then we should eventually get a clearer picture of what these microbial communities actually do. And that could turn into fresh healthcare strategies, meant to improve outcomes for human health.

References

Arrieta, M. C., Stiemsma, L. T., Amenyogbe, N., Brown, E. M., & Finlay, B. B. (2014). The intestinal microbiome in early life: Health and disease. *Frontiers in Immunology, 5*(427), 1–18. https://doi.org/10.3389/fimmu.2014.00427

Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004). The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the National Academy of Sciences of the United States of America, 101*(44), 15718–15723. https://doi.org/10.1073/pnas.0407076101

Bäckhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A., & Gordon, J. I. (2005). Host-bacterial mutualism in the human intestine. *Science, 307*(5717), 1915–1920. https://doi.org/10.1126/science.1104816

Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. *Cell, 157*(1), 121–141. https://doi.org/10.1016/j.cell.2014.03.011

Cani, P. D., & Delzenne, N. M. (2009). The role of the gut microbiota in energy metabolism and metabolic disease. *Current Pharmaceutical Design, 15*(13), 1546–1558. https://doi.org/10.2174/138161209788168164

Cho, I., & Blaser, M. J. (2012). The human microbiome: At the interface of health and disease. *Nature Reviews Genetics, 13*(4), 260–270. https://doi.org/10.1038/nrg3182

Costello, E. K., Lauber, C. L., Hamady, M., Fierer, N., Gordon, J. I., & Knight, R. (2009). Bacterial community variation in human body habitats across space and time. *Science, 326*(5960), 1694–1697. https://doi.org/10.1126/science.1177486

Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., ... Dinan, T. G. (2019). The microbiota-gut-brain axis. *Physiological Reviews, 99*(4), 1877–2013. https://doi.org/10.1152/physrev.00018.2018

Fan, Y., & Pedersen, O. (2021). Gut microbiota in human metabolic health and disease. *Nature Reviews Microbiology, 19*(1), 55–71. https://doi.org/10.1038/s41579-020-0433-9

Flint, H. J., Scott, K. P., Louis, P., & Duncan, S. H. (2012). The role of the gut microbiota in nutrition and health. *Nature Reviews Gastroenterology & Hepatology, 9*(10), 577–589. https://doi.org/10.1038/nrgastro.2012.156

Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018). Current understanding of the human microbiome. *Nature Medicine, 24*(4), 392–400. https://doi.org/10.1038/nm.4517

Honda, K., & Littman, D. R. (2016). The microbiota in adaptive immune homeostasis and disease. *Nature, 535*(7610), 75–84. https://doi.org/10.1038/nature18848

Human Microbiome Project Consortium. (2012). Structure, function and diversity of the healthy human microbiome. *Nature, 486*(7402), 207–214. https://doi.org/10.1038/nature11234

Jandhyala, S. M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M., & Reddy, D. N. (2015). Role of the normal gut microbiota. *World Journal of Gastroenterology, 21*(29), 8787–8803. https://doi.org/10.3748/wjg.v21.i29.8787

Kho, Z. Y., & Lal, S. K. (2018). The human gut microbiome—A potential controller of wellness and disease. *Frontiers in Microbiology, 9*, 1835. https://doi.org/10.3389/fmicb.2018.01835

Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell, 165*(6), 1332–1345. https://doi.org/10.1016/j.cell.2016.05.041

Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006). Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell, 124*(4), 837–848. https://doi.org/10.1016/j.cell.2006.02.017

Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. *New England Journal of Medicine, 375*(24), 2369–2379. https://doi.org/10.1056/NEJMra1600266

Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012). Host-gut microbiota metabolic interactions. *Science, 336*(6086), 1262–1267. https://doi.org/10.1126/science.1223813

Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., Mende, D. R., Li, J., Xu, J., Li, S., Li, D., Cao, J., Wang, B., Liang, H., Zheng, H., … Wang, J. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature, 464*(7285), 59–65. https://doi.org/10.1038/nature08821

Round, J. L., & Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. *Nature Reviews Immunology, 9*(5), 313–323. https://doi.org/10.1038/nri2515

Sender, R., Fuchs, S., & Milo, R. (2016). Revised estimates for the number of human and bacterial cells in the body. *PLoS Biology, 14*(8), e1002533. https://doi.org/10.1371/journal.pbio.1002533

Sommer, F., & Bäckhed, F. (2013). The gut microbiota—Masters of host development and physiology. *Nature Reviews Microbiology, 11*(4), 227–238. https://doi.org/10.1038/nrmicro2974

Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004). Dysbiosis in inflammatory bowel disease. *Gut, 53*(1), 1–4. https://doi.org/10.1136/gut.53.1.1

Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016). The microbiome and innate immunity. *Nature, 535*(7610), 65–74. https://doi.org/10.1038/nature18847

Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007). The human microbiome project. *Nature, 449*(7164), 804–810. https://doi.org/10.1038/nature06244

Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., Egholm, M., Henrissat, B., Heath, A. C., Knight, R., & Gordon, J. I. (2009). A core gut microbiome in obese and lean twins. *Nature, 457*(7228), 480–484. https://doi.org/10.1038/nature07540

Ursell, L. K., Metcalf, J. L., Parfrey, L. W., & Knight, R. (2012). Defining the human microbiome. *Nutrition Reviews, 70*(Suppl. 1), S38–S44. https://doi.org/10.1111/j.1753-4887.2012.00493.x

Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010). Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science, 328*(5975), 228–231. https://doi.org/10.1126/science.1179721

Young, V. B. (2017). The role of the microbiome in human health and disease: An introduction for clinicians. *BMJ, 356*, j831. https://doi.org/10.1136/bmj.j831

Zmora, N., Suez, J., & Elinav, E. (2019). You are what you eat: Diet, health and the gut microbiota. *Nature Reviews Gastroenterology & Hepatology, 16*(1), 35–56. https://doi.org/10.1038/s41575-018-0061-2